Challenges in the harmonization of immune monitoring studies and trial design for cell-based therapies in the context of hematopoietic cell transplantation for pediatric cancer patients

Cytotherapy

Volumn 17, Issue 12, 2015, Pages 1667-1674

  Nierkens, Stefan ^a   Lankester, Arjan C ^b   Egeler, R Maarten ^c   Bader, Peter ^d   Locatelli, Franco ^e,f   Pulsipher, Michael A ^g   Bollard, Catherine M ^h   Boelens, Jaap Jan ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^c HOSPITAL FOR SICK CHILDREN   (Canada)

^d Practice for Child and Adolescent Psychiatry   (Germany)

^e BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^f UNIVERSITY OF PAVIA   (Italy)

^g UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^h GEORGE WASHINGTON UNIVERSITY   (United States)

Author keywords

Cell based therapy; Clinical trial design; Hematopoietic cell transplantation, immune monitoring; Pediatric cancer

Indexed keywords

BIOASSAY; BIOINFORMATICS; CELL THERAPY; CELL TRANSPLANTATION; CHILDHOOD CANCER; CLINICAL EFFECTIVENESS; CLINICAL PROTOCOL; CLINICAL TRIAL (TOPIC); GENETIC VARIABILITY; HEMATOPOIETIC CELL TRANSPLANTATION; HUMAN; IMMUNOCOMPETENT CELL; MINIMAL RESIDUAL DISEASE; OUTCOME ASSESSMENT; PATIENT MONITORING; PHENOTYPE; PRIORITY JOURNAL; REVIEW; STUDY DESIGN; TREATMENT INDICATION; VIRUS LOAD; VIRUS REACTIVATION; ADOLESCENT; BIOLOGICAL THERAPY; CHILD; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOLOGICAL MONITORING; METHODOLOGY; NEOPLASMS; PROCEDURES;

ADOLESCENT; CELL- AND TISSUE-BASED THERAPY; CHILD; CLINICAL TRIALS AS TOPIC; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MONITORING, IMMUNOLOGIC; NEOPLASMS; RESEARCH DESIGN;

EID: 84947545452     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.1016/j.jcyt.2015.09.008     Document Type: Review

References (36)

1. Butterfield L.H., Vujanovic L., Pardee A.D. Approaches to immunologic monitoring of clinical trials. The tumor immunoenvironment 2013, 663-694. Springer Netherlands, Dordrecht. 10.1007/978-94-007-6217-6_29.
2. Whiteside T.L. Immune responses to cancer: are they potential biomarkers of prognosis?. Front Oncol 2013, 3:107. 10.3389/fonc.2013.00107.
3. Admiraal R., van Kesteren C., Jol-van der Zijde C.M., Lankester A.C., Bierings M.B., Egberts T.C.G., et al. Association between anti-thymocyte globulin exposure and CD4+ immune reconstitution in paediatric haemopoietic cell transplantation: a multicentre, retrospective pharmacodynamic cohort analysis. Lancet Haematol 2015, 2:e194-203. 10.1016/S2352-3026(15)00045-9.
4. de Koning C., Plantinga M., Besseling P., Boelens J.J., Nierkens S. Immune-reconstitution after allogeneic hematopoietic cell transplantation in children. Biol Blood Marrow Transplant 2015, 10.1016/j.bbmt.2015.08.028.
5. Pidala J., Lee S.J., Ahn K.W., Spellman S., Wang H.-L., Aljurf M., et al. Nonpermissive HLA-DPB1 mismatch increases mortality after myeloablative unrelated allogeneic hematopoietic cell transplantation. Blood 2014, 124:2596-2606. 10.1182/blood-2014-05-576041.
6. Giebel S., Locatelli F., Lamparelli T., Velardi A., Davies S., Frumento G., et al. Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors. Blood 2003, 102:814-819. 10.1182/blood-2003-01-0091.
7. Delgado D.C., Hank J.A., Kolesar J., Lorentzen D., Gan J., Seo S., et al. Genotypes of NK cell KIR receptors, their ligands, and Fcγ receptors in the response of neuroblastoma patients to Hu14.18-IL2 immunotherapy. Cancer Res 2010, 70:9554-9561. 10.1158/0008-5472.CAN-10-2211.
8. Cartron G., Dacheux L., Salles G., Solal-Celigny P., Bardos P., Colombat P., et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene. Blood 2002, 99:754-758. 10.1182/blood.V99.3.754.
9. Bibeau F., Lopez-Crapez E., Di Fiore F., Thezenas S., Ychou M., Blanchard F., et al. Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan. J Clin Oncol 2009, 27:1122-1129. 10.1200/JCO.2008.18.0463.
10. Zhang W., Gordon M., Schultheis A.M., Yang D.Y., Nagashima F., Azuma M., et al. FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab. J Clin Oncol 2007, 25:3712-3718. 10.1200/JCO.2006.08.8021.
11. Musolino A., Naldi N., Bortesi B., Pezzuolo D., Capelletti M., Missale G., et al. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J Clin Oncol 2008, 26:1789-1796. 10.1200/JCO.2007.14.8957.
12. Wang E., Zhao Y., Monaco A., Uccellini L., Kirkwood J.M., Spyropoulou-Vlachou M., et al. A multi-factorial genetic model for prognostic assessment of high risk melanoma patients receiving adjuvant interferon. PLoS ONE 2012, 7:e40805. 10.1371/journal.pone.0040805.
13. Bartelink I.H., Belitser S.V., Knibbe C.A.J., Danhof M., de Pagter A.J., Egberts T.C.G., et al. Immune reconstitution kinetics as an early predictor for mortality using various hematopoietic stem cell sources in children. Biol Blood Marrow Transplant 2013, 19:305-313. 10.1016/j.bbmt.2012.10.010.
14. Rubio M.-T., Moreira-Teixeira L., Bachy E., Bouillié M., Milpied P., Coman T., et al. Early posttransplantation donor-derived invariant natural killer T-cell recovery predicts the occurrence of acute graft-versus-host disease and overall survival. Blood 2012, 120:2144-2154. 10.1182/blood-2012-01-404673.
15. Chester C., Marabelle A., Houot R., Kohrt H.E. Dual antibody therapy to harness the innate anti-tumor immune response to enhance antibody targeting of tumors. Curr Opin Immunol 2015, 33C:1-8. 10.1016/j.coi.2014.12.010.
16. Döring M., Rohrer K.M., Erbacher A., Gieseke F., Schwarze C.-P., Bader P., et al. Human leukocyte antigen DR surface expression on CD14+ monocytes during adverse events after hematopoietic stem cell transplantation. Ann Hematol 2015, 94:265-273. 10.1007/s00277-014-2185-y.
17. Döring M., Cabanillas Stanchi K.M., Haufe S., Erbacher A., Bader P., Handgretinger R., et al. Patterns of monocyte subpopulations and their surface expression of HLA-DR during adverse events after hematopoietic stem cell transplantation. Ann Hematol 2015, 94:825-836. 10.1007/s00277-014-2287-6.
18. van Cruijsen H., van der Veldt A.A.M., Vroling L., Oosterhoff D., Broxterman H.J., Scheper R.J., et al. Sunitinib-induced myeloid lineage redistribution in renal cell cancer patients: CD1c+ dendritic cell frequency predicts progression-free survival. Clin Cancer Res 2008, 14:5884-5892. 10.1158/1078-0432.CCR-08-0656.
19. Finkelstein S.E., Carey T., Fricke I., Yu D., Goetz D., Gratz M., et al. Changes in dendritic cell phenotype after a new high-dose weekly schedule of interleukin-2 therapy for kidney cancer and melanoma. J Immunother 2010, 33:817-827. 10.1097/CJI.0b013e3181ecccad.
20. Bergmann C., Strauss L., Wang Y., Szczepanski M.J., Lang S., Johnson J.T., et al. T regulatory type 1 cells in squamous cell carcinoma of the head and neck: mechanisms of suppression and expansion in advanced disease. Clin Cancer Res 2008, 14:3706-3715. 10.1158/1078-0432.CCR-07-5126.
21. Whiteside T.L., Schuler P., Schilling B. Induced and natural regulatory T cells in human cancer. Expert Opin Biol Ther 2012, 12:1383-1397. 10.1517/14712598.2012.707184.
22. Kvistborg P., Philips D., Kelderman S., Hageman L., Ottensmeier C., Joseph-Pietras D., et al. Anti-CTLA-4 therapy broadens the melanoma-reactive CD8+ T cell response. Sci Transl Med 2014, 6. 254ra128. 10.1126/scitranslmed.3008918.
23. Aarntzen E.H.J.G., Figdor C.G., Adema G.J., Punt C.J.A., De Vries I.J.M. Dendritic cell vaccination and immune monitoring. Cancer Immunol Immunother 2008, 57:1559-1568. 10.1007/s00262-008-0553-y.
24. Streitz M., Miloud T., Kapinsky M., Reed M.R., Magari R., Geissler E.K., et al. Standardization of whole blood immune phenotype monitoring for clinical trials: panels and methods from the ONE study. Transplant Res 2013, 2(1):17. 10.1186/2047-1440-2-17.
25. Bendall S.C., Simonds E.F., Qiu P., Amir E.-A.D., Krutzik P.O., Finck R., et al. Single-cell mass cytometry of differential immune and drug responses across a human hematopoietic continuum. Science 2011, 332:687-696. 10.1126/science.1198704.
26. Clay T.M., Hobeika A.C., Mosca P.J., Lyerly H.K., Morse M.A. Assays for monitoring cellular immune responses to active immunotherapy of cancer. Clin Cancer Res 2001, 7:1127-1135.
27. Keustermans G.C.E., Hoeks S.B.E., Meerding J.M., Prakken B.J., de Jager W. Cytokine assays: an assessment of the preparation and treatment of blood and tissue samples. Methods 2013, 61:10-17. 10.1016/j.ymeth.2013.04.005.
28. de Jager W., Bourcier K., Rijkers G.T., Prakken B.J., Seyfert-Margolis V. Prerequisites for cytokine measurements in clinical trials with multiplex immunoassays. BMC Immunol 2009, 10:52. 10.1186/1471-2172-10-52.
29. Mamessier E., Pradel L.C., Thibult M.-L., Drevet C., Zouine A., Jacquemier J., et al. Peripheral blood NK cells from breast cancer patients are tumor-induced composite subsets. J Immunol 2013, 190:2424-2436. 10.4049/jimmunol.1200140.
30. Feuchtinger T., Opherk K., Bethge W.A., Topp M.S., Schuster F.R., Weissinger E.M., et al. Adoptive transfer of pp65-specific T cells for the treatment of chemorefractory cytomegalovirus disease or reactivation after haploidentical and matched unrelated stem cell transplantation. Blood 2010, 116:4360-4367. 10.1182/blood-2010-01-262089.
31. Leen A.M., Bollard C.M., Mendizabal A.M., Shpall E.J., Szabolcs P., Antin J.H., et al. Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation. Blood 2013, 121:5113-5123. 10.1182/blood-2013-02-486324.
32. Grimwade D., Freeman S.D. Defining minimal residual disease in acute myeloid leukemia: which platforms are ready for "prime time?". Hematology 2014, 2014:222-233. 10.1182/asheducation-2014.1.222.
33. Jaso J.M., Wang S.A., Jorgensen J.L., Lin P. Multi-color flow cytometric immunophenotyping for detection of minimal residual disease in AML: past, present and future. Bone Marrow Transplant 2014, 49:1129-1138. 10.1038/bmt.2014.99.
34. Pulsipher M.A., Carlson C., Langholz B., Wall D.A., Schultz K.R., Bunin N., et al. IgH-V(D)J NGS-MRD measurement pre- and early post- allo-transplant defines very low and very high risk ALL patients. Blood 2015, 125(22):3501-3508. 10.1182/blood-2014-12-615757.
35. Lindell Osuagwu L., Korhonen M.J., Saano S., Helin Tanninen M., Naaranlahti T., Kokki H. Off-label and unlicensed drug prescribing in three paediatric wards in Finland and review of the international literature. J Clin Pharm Ther 2009, 34:277-287. 10.1111/j.1365-2710.2008.01005.x.
36. Bellutti Enders F., van Wijk F., Scholman R., Hofer M., Prakken B.J., van Royen Kerkhof A., et al. CXCL10, TNFR2 and Galectin-9 correlate with disease activity in Juvenile Dermatomyositis. Arthritis Rheum 2014, 66(8):2281-2289. 10.1002/art.38676.